Physician profile
Michael Andre Taylor
NPI 1871596502
$1,391.27
in general payments reported to CMS, 2019-2025
21 companies · $62.42 in 2025
The $62.42 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $289 · 2022: $132 · 2023: $368 · 2024: $540 · 2025: $62.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $204.10 | 2021 | |
| Janssen Biotech, INC. | $135.24 | 2023 | Carvykti, Darzalex, Tecvayli |
| Novocure INC. | $132.54 | 2024 | Optune |
| E.R. Squibb & Sons, L.L.C. | $115.33 | 2022-2023 | Opdivo |
| Eisai INC. | $110.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $103.94 | 2023 | Libtayo |
| Astrazeneca Pharmaceuticals Lp | $89.06 | 2024 | Enhertu, Tagrisso |
| Intuitive Surgical, INC. | $85.12 | 2021 | |
| Abbvie INC. | $56.25 | 2024 | |
| Dendreon Pharmaceuticals LLC | $51.75 | 2023 | Provenge |
| Boston Scientific Corporation | $46.50 | 2025 | Spaceoar Vue System - 10ml |
| Progenics Pharmaceuticals, INC. | $43.72 | 2024 | |
| Elekta, INC. | $37.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $35.32 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $28.54 | 2023 | Keytruda |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $27.40 | 2023 | Imbruvica |
| Myriad Genetic Laboratories, INC. | $22.27 | 2024 | Myrisk |
| Lilly USA, LLC | $20.73 | 2024 | Retevmo, Jaypirca, Verzenio |
| Genmab U.S., INC. | $18.03 | 2024 | Epkinly |
| Blueprint Medicines Corporation | $14.76 | 2024 | Ayvakit |
| Celgene Corporation | $13.62 | 2024 | Pomalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.